HONYA Medical

04/05/2025

📢 HONYA Medical (鴻曜醫學) Joins Forces in Taiwan–Australia Biotech Collaboration

We are proud to participate in the BioConnect Forum, representing Taiwan’s regenerative medicine strength on a global stage. Through this event, HONYA Medical (鴻曜醫學) explores future collaboration opportunities in the field of stem cell innovation, clinical trials, and international partnerships.

🔗 Read the full coverage from GeneOnline:
https://www.geneonline.com/strengthening-biotech-ties-highlights-from-the-bioconnect-forum-and-future-collaboration-between-taiwan-and-australia/

#鴻曜醫學 #再生醫學

04/05/2025

📣 鴻曜醫學參與 BioConnect Forum，推動臺澳再生醫療合作

鴻曜醫學參由經濟部生技醫藥產業發展推動小組(BPIPO)、南部科學園區管理局(Southern Taiwan Science Park Bureau)、生物技術開發中心(DCB)及澳洲駐台辦事處(Australian Office in Taipei)共同主辦的 「BioConnect:澳洲-臺灣生技論壇(BioConnect: Australia-Taiwan Biotech Forum)」在澳洲墨爾本圓滿舉行，積極拓展與澳洲在幹細胞臨床試驗、再生醫學及國際合作上的新契機。

(Photo source/credit : GeneOnline )

🔗 相關報導連結（GeneOnline）： https://geneonline.news/strengthening-biotech-ties-highlights-from-the-bioconnect-forum-and-future-collaboration-between-taiwan-and-australia/

#鴻曜醫學 #再生醫學 #幹細胞 #臺澳合作 #台灣生技

01/05/2025

📢 HONYA Medical (鴻曜醫學) Engages in Taiwan–Australia Biotech Collaboration

We are proud to be part of the ongoing efforts to strengthen biotech ties between Taiwan and Australia. Our participation in the BioConnect Forum highlights our dedication to advancing regenerative medicine and stem cell research.

🔗 Read more in GeneOnline’s latest coverage:
https://geneonline.news/strengthening-biotech-ties-highlights-from-the-bioconnect-forum-and-future-collaboration-between-taiwan-and-australia/

#鴻曜醫學 #再生醫學

10 月 28 日，由經濟部生技醫藥產業發展推動小組（BPIPO）、南部科學園區管理局（Southern TaRead More

16/09/2023

Exciting news in cardiovascular research! Investigational stem cells show promise in recent heart attack patients. MiSaver stem cells are safe and may improve outcomes. Learn more in the reference link : https://doi.org/10.1101/2023.08.17.23294118
.

28/08/2023

Promising Findings: MiSaver® Stem Cells Show Potential for Heart Function Recovery in Heart Attack Patients

We are pleased to share our results from our Phase IIa clinical trial investigating the potential benefits of MiSaver® stem cells in heart attack patients. Early data suggests that MiSaver® stem cells may have a positive impact on heart function recovery.

While these findings are encouraging, it's important to note that the trial is still in the experimental phase, and further research is needed to validate these initial observations.

18/07/2023

In the realm of medical breakthroughs, a silent hero emerges, its story untold by conventional means. HONYA Medical's investigational drug, MiSaver's, has unveiled promising results in Phase I/IIa clinical trials. With unwavering dedication, the team brings hope to patients who have suffered heart attacks, with the potential to improve heart function and ignite the flame of vitality. As the transformative journey continues, HONYA Medical envisions a future where hearts are mended and lives rejuvenated.
Within the corridors of hope, the whispers of success echo. Mi, the beacon of promise, illuminates a path towards a brighter tomorrow. Patient by patient, beat by beat, HONYA Medical's commitment to rewriting the narrative of heart health remains steadfast. Silent yet powerful, MiSaver's triumph resonates deeply, reminding us of the boundless potential that lies within the tireless pursuit of scientific exploration.

12/06/2023

HONYA Medical, the dedicated team of scientists, has achieved promising results in Phase I/IIa clinical trials. Their groundbreaking medical treatment has shown encouraging potential, instilling hope for a brighter future. With unwavering determination and positive outcomes, HONYA Medical is poised to embark on the next phase of their transformative scientific journey. "

03/04/2023

I believe that when it comes to evaluating a cell therapy CDMO's ability to support early clinical therapy, there's nothing quite like HONYA Medical. Just like our track record of conducting safe and effective clinical trials speaks for itself.

When assessing the capabilities of a cell therapy CDMO, it is crucial to consider their past achievements and safety records in clinical trials. And that's where HONYA Medical shines. With proven success in conducting clinical trials, ensuring both safety and efficacy, HONYA has established as the go-to partner for early clinical therapy support. HONYA Medical's exceptional expertise and credibility make a top choice for advancing breakthrough treatments.

https://www.linkedin.com/feed/update/urn:li:groupPost:135553-7079899945272532992/?commentUrn=urn%3Ali%3Acomment%3A%28groupPost%3A135553-7079899945272532992%2C7081806335809359872%29

(This message is provided for informational purposes only and should not be construed as legal or professional advice.)

16/03/2023

Many patients were helped using their own stem cells, new small blood vessels were formed in their hearts and lead to a better blood circulation . Professor Lee’s team found the improvement results were related on the quality of their own stem cells.

We prepared (manufactured OEM) stem cells products for them so patients can use much younger stem cells and don’t have to go through the stem cell harvesting procedures at their difficult times.

09/03/2023

A typically stem cell from HONYA® Ithun M2 has the capacity to divide over 20 times or 2^20 , which is more than 1 million, that mathematically calculates a vial of HONYA® Ithun M2 stem cells, containing more than 100,000,000 cells, given the best growth environment may give rise to 100,000,000,000,000 cells!

09/03/2023

Every unit of the HONYA® Ithun M2 contains over a hundred million cells and has high regenerative potential and is suitable for a variety of applications. This stem cell product line is the backbone to some states-of-the-art clinical treatment trials with encouraging and exciting results.

22/02/2023

Doctors trialing with stem cells have experienced benefits of stem cells to their patients. There’s a improvement in daily functional capability level - capable of doing more physically and to stay independently. This improvement is distinct from increasing survival, living longer or extending the life span.